Fresenius


Reassuring Q2 results; H2 improvements remain eagerly awaited

06/08/25 -"Fresenius posted encouraging Q2 2025 results, with €5.6bn in sales (+5%) and adjusted EBIT coming ahead of street expectations. Both segments clocked valuable top-line gains – with a massive uptick ..."

Pages
60
Language
English
Published on
06/08/25
You may also be interested by these reports :
11/08/25
We have revisited the amortisation expenses and negative FX hedging results for FY2024-25 and, as a result for the current fiscal year, our EPS ...

07/08/25
CZM’s Q3 sales met expectations, driven by Microsurgery, while Ophthalmology remained stable. The FY2024-25 guidance remains unchanged. However, a ...

06/08/25
Fresenius posted encouraging Q2 2025 results, with €5.6bn in sales (+5%) and adjusted EBIT coming ahead of street expectations. Both segments clocked ...

06/08/25
Qiagen exceeded market expectations and management’s guidance in Q2, driven by robust growth in Diagnostic Solutions and contributions from ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO